Lenvatinib after liver cancer surgery to prevent recurrence
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had surgery to remove your liver cancer 4 to 8 weeks ago, and doctors confirmed no cancer cells were left behind.
- Your cancer is only in the liver and has not spread to blood vessels or other organs.
- You have at least one high-risk factor: tumor larger than 5 cm, more than 3 tumors, signs of blood vessel invasion, or certain tumor grades.
- Your liver and kidney function, blood counts, and clotting are within safe limits as checked by recent tests.
- You are willing to use reliable birth control during the study and for 60 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral targeted therapy drugs, lenvatinib and regorafenib, in people with advanced liver cancer (hepatocellular carcinoma) that has progressed after first-line immunotherapy-based treatment. The goal is to see if these drugs can control the cancer and improve outcomes.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests whether adding a targeted therapy (lenvatinib) to standard chemotherapy after a liver transplant can help prevent liver cancer from coming back. It may be an option for patients who have had a transplant and want to reduce the risk of recurrence.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.